Pharmaco - Press Releases

Date	Title	Company
21-Dec-2021	Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline	Merck
21-Dec-2021	Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome	Zogenix
21-Dec-2021	Integrity Applications Issues Shareholder Update Letter	Integrity Applications, Inc.
21-Dec-2021	Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics	Sanofi
21-Dec-2021	Aqilion presents Nomination Committee for the 2022 Annual General Meeting	Aqilion
21-Dec-2021	Novo Holdings invests EUR 86 million in 21st.BIO, a new bioindustrial scale-up company building on technology base from Novozymes	Novo Holdings
21-Dec-2021	Tezspire (tezepelumab) approved in the US for severe asthma	AstraZeneca and Amgen
21-Dec-2021	Strong growth for DOUGLAS in Q4 thanks to e-commerce and re-opened stores	Douglas GmbH
20-Dec-2021	SynBiotic SE and key.force: Joint Venture for Germany's largest cannabis sales team	SynBiotic SE
20-Dec-2021	Advancing AI Drug Discovery in Clinical Trials at SMi’s 3rd Annual AI in Drug Discovery Conference	SMi Group
20-Dec-2021	Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics’ Innovative Splicing Platform	PTC Therapeutics
20-Dec-2021	SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Conference with Online Access Only	SMi Group
20-Dec-2021	MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval	MagForce AG
17-Dec-2021	aap: Supervisory Board extends Management Board contracts until end of 2023	aap Implantate AG
17-Dec-2021	Douglas GmbH: Earnings call - Release of results for the fourth quarter 2020/21 (ending 30 September 2021) on 21 December 2021	Douglas GmbH
17-Dec-2021	NICE Recommends VENCLYXTO®▼(Venetoclax) Combination in Certain Patients with the Aggressive Blood Cancer Acute Myeloid Leukaemia (AML)	Abbvie UK
17-Dec-2021	Arix Bioscience PLC: Director/PDMR Shareholdings	Arix Bioscience PLC
17-Dec-2021	ProBioGen's GlymaxX® Technology Reaches Phase III Clinical Development	B3C newswire
17-Dec-2021	COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.	Cassiopea S.p.A.
17-Dec-2021	COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.	Cosmo Pharmaceuticals N.V.